FDA Approves SynGenX-1000 Cord Blood Processing Platform

A company that makes products for extracting stem cells from a variety of sources, SynGen Inc., of Sacramento, CA, has received the FDA nod for its SynGenX-1000 platform.

The SynGenX-1000 platform is capable of harvesting stem cells from umbilical cord blood.

Philip Coelho, CEO of SynGen, said "This �next generation' SynGenX�-1000 System improves the recovery of stem and progenitor cells from cord blood units, which should increase the number of clinical grade units available for transplantation. The CryoPRO-2� simplifies the cryopreservation workflow for cord blood bank personnel and provides a medical record of the process. The SynGen� DataTrak software captures the data associated with processing each cord blood unit for the blood bank's records."

Source: Medindia